Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • genbio64
    Member
    • Dec 2009
    • 42

    TruSeq vs Nexterra

    I was wondering if anyone had an empirical evidence in the comparison between the TruSeq and Nexterra protocols? We have been considering switching over to the Epicentre products exclusively but lack any definitive evidence of performance. Does anyone have an argument either way?
  • pmiguel
    Senior Member
    • Aug 2008
    • 2328

    #2
    First, Epicentre now is owned by Illumina, so no difference there.

    Second, "Nextera" is a mixture of several component methodologies:

    (1) "Tagmentation" (in vitro transposase action) is used instead of sonication or other methods of mechanical fragmentation.
    (2) Dual indexes (one in each adapter) are deployed rather than the single indexes of TruSeq.
    (3) At least for NexteraXT, "normalization" beads are used equalize all the libraries to be included in a single pool.
    (4) The lower concentration of resulting library pools is compensated for by using a heat denaturation, rather than a base denaturation prior to clustering. This may be possible because the products come off the normalization beads as ssDNA.

    We have not yet run any Nextera libraries. But the process does look streamlined -- especially for handling library construction for large numbers of samples (eg 96).

    --
    Phillip

    Comment

    • Olaf Blue
      Member
      • Nov 2010
      • 58

      #3
      Also....Nextera is now sold by Illumina, not Epicentre. Epicentre stopped selling the Nextera version 1 kits On Dec 31, 2011, and the Version 2 is now sold exclusively through Illumina.

      Comment

      • genbio64
        Member
        • Dec 2009
        • 42

        #4
        Thanks but I was referring to sequencing performance? For example, sample coverage, anymore or less 5' or 3' bias, coverage of exons vs introns, coding vs non-coding genes?

        Comment

        • Olaf Blue
          Member
          • Nov 2010
          • 58

          #5
          you will need to contact Illumina regarding these parameters; I understand that Illumina has improved performance specs.

          Comment

          • SarahNGS
            Member
            • Nov 2011
            • 17

            #6
            shearing differences

            I'm told (but have no direct experience) that the "tagmentation" step, which uses enzymatic fragmentation via an engineered transposase, has some non-randomness that could potentially result in reduced coverage in certain areas. The transposase has some sequence specificity that you'd have to look up. But the sample prep sure is easy!

            Comment

            • Olaf Blue
              Member
              • Nov 2010
              • 58

              #7
              As I understand it, that's correct...minor G-bias.

              Comment

              Latest Articles

              Collapse

              • mylaser
                Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by mylaser
                Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
                If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
                This guide explains everything you need to know about...
                Today, 01:13 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM
              • SEQadmin2
                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                by SEQadmin2



                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                07-08-2026, 05:17 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, 07-09-2026, 10:04 AM
              0 responses
              17 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-08-2026, 10:08 AM
              0 responses
              10 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-07-2026, 11:05 AM
              0 responses
              22 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-02-2026, 11:08 AM
              0 responses
              31 views
              0 reactions
              Last Post SEQadmin2  
              Working...